Abbott and OraSure to take rapid HIV-1 test to US
This article was originally published in Clinica
Abbott and OraSure Technologies are to co-market a rapid HIV-1 test in the US. Abbott will concentrate on the hospital and physician's office lab markets, while OraSure will sell mainly to the public health and criminal justice markets.
You may also be interested in...
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.